BioArctic AB's (publ) (NASDAQ STOCKHOLM: BIOA B) partner Eisai today announced today that Leqembi® (generic name: lecanemab) has been launched in South Korea. Leqembi received approval in South Korea ...

Fintica AI Ltd, a leading innovator in next-generation AI solutions for capital markets, and Legend Arb Trading Limited, a Hong Kong-based proprietary trading firm with a global footprint across major ...

at 19:31 "LEQEMBI®" (Lecanemab) for the Treatment of Alzheimer's Disease Launched in South Korea Eisai Co., Ltd.

Eisai (ESAIY) and Biogen (BIIB) announced that the humanized anti-soluble aggregated amyloid-beta, or Abeta, monoclonal antibody Leqembi has been launched in South Korea. Leqembi received the Ministry ...

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: ...

We recently compiled a list of the 10 Worst Performing Healthcare Stocks in 2024. In this article, we are going to take a ...

November is National Alzheimer’s Awareness Month.The Alliance for Aging Research is using this month to raise awareness about ...

Eisai and the National Center of Neurology and Psychiatry in Tokyo will study the link between APOE genotype and safety and efficacy of Leqembi.

Rosa-Grilo incorporated Wave-CAIPI into the diagnostic scanning protocol used at UCL’s memory clinic. It comprises four sequences: T1-weighted 3D, T2-weighted 2D, T2-weighted 3D, and 3D FLAIR imaging.

The earlier MCI due to AD and mild AD dementia are diagnosed and treated, the greater the opportunity for benefit.

On Tuesday, UCB SA (OTC:UCBJY) (OTC:UCBJF) and Biogen Inc. (NASDAQ:BIIB) presented detailed results from the Phase 3 PHOENYCS ...

Trump fingers Robert F. Kennedy Jr. to lead the HHS, lupus and ATTR-CM dominate headlines this week, bluebird bio has a cash gap to leap and RegenxBio eyes Sarepta in Duchenne muscular dystrophy.